Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Hartmann

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyC Bokemeyer, I Bondarenko, J T Hartmann, et al.
Cancer|October 8, 1997
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomasC Bokemeyer, A Franzke, J T Hartmann, et al.
British Journal of Cancer|May 13, 2004
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancerR-D Hofheinz, A Willer, A Weisser, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 2005
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancerJ Wierecky, C Kollmannsberger, I Boehlke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)E Goekkurt, S-E Al-Batran, U Mogck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumorsC Massard, A Kramar, J Beyer, et al.
International Journal of Cancer|December 22, 1999
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)C Bokemeyer, C Kollmannsberger, A Harstrick, et al.
British Journal of Cancer|July 3, 2003
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trialC Bokemeyer, N Schleucher, B Metzner, et al.
World Journal of Urology|February 25, 2005
Impact of tumor size on the long-term survival of patients with early stage renal cell cancerM Kuczyk, G Wegener, A S Merseburger, et al.
British Journal of Cancer|August 17, 2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerC Kollmannsberger, D Quietzsch, C Haag, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyC Bokemeyer, I Bondarenko, J T Hartmann, et al.
Cancer|October 8, 1997
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomasC Bokemeyer, A Franzke, J T Hartmann, et al.
British Journal of Cancer|May 13, 2004
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancerR-D Hofheinz, A Willer, A Weisser, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 2005
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancerJ Wierecky, C Kollmannsberger, I Boehlke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)E Goekkurt, S-E Al-Batran, U Mogck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumorsC Massard, A Kramar, J Beyer, et al.
International Journal of Cancer|December 22, 1999
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)C Bokemeyer, C Kollmannsberger, A Harstrick, et al.
British Journal of Cancer|July 3, 2003
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trialC Bokemeyer, N Schleucher, B Metzner, et al.
World Journal of Urology|February 25, 2005
Impact of tumor size on the long-term survival of patients with early stage renal cell cancerM Kuczyk, G Wegener, A S Merseburger, et al.
British Journal of Cancer|August 17, 2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerC Kollmannsberger, D Quietzsch, C Haag, et al.
Pageof 12